Treace Medical Concepts (TMCI)
NASDAQ:TMCI
TMCI Stock Chart & Stats
$1.28
-$0.15(-1.96%)
At close: 4:00 PM EST
$1.28
-$0.15(-1.96%)
Day’s Range― - ―
52-Week Range$1.19 - $8.87
Previous CloseN/A
Volume76.56K
Average Volume (3M)918.48K
Market Cap
$82.68M
Enterprise Value$82.07M
Total Cash (Recent Filing)$48.37M
Total Debt (Recent Filing)$13.98M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
May 13, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding64,590,500
10 Day Avg. Volume1,009,218
30 Day Avg. Volume918,480
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.77
Price to Sales (P/S)0.73
P/FCF Ratio-5.26
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue0.39
Enterprise Value/Gross Profit0.48
Enterprise Value/Ebitda-1.91
Forecast
1Y Price Target
$3.56Price Target Upside178.13% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$205.32M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~80% gross margins indicate strong per-procedure economics and pricing power for implants and instrumentation. Durable margin levels give the business structural flexibility to invest in sales and training while requiring fewer incremental revenue dollars to approach operating leverage as adoption scales.
Surgeon Adoption & TAM ExpansionA rapidly expanding active surgeon base and multi-product launches broaden the company’s addressable market and create stickiness around the Lapiplasty platform. Durable adoption trends and new systems that management estimates expand TAM materially support recurring, procedure-driven revenue over the medium term.
Improved Liquidity & Lower LeverageMaterial reduction in debt alongside ~$48M cash and a $115M credit facility materially improves financial flexibility. This reduced leverage and available liquidity lower refinancing risk and give management time to execute product launches and surgeon training without immediate funding pressure.
Bears Say
Persistent Operating Losses & Negative FCFOperating losses and negative free cash flow remain structural constraints: even after burn improvement the company cannot self-fund growth. Persistent cash deficits increase reliance on external capital, limit margin expansion cadence, and raise execution and dilution risk if revenue recovery stalls.
Revenue Stalled And Weak GuidanceGuidance implying flat-to-declining full-year revenue signals a plateau in procedure volumes and commercial traction. A sustained revenue plateau undermines operating leverage and lengthens the timeline to profitability, increasing dependence on successful higher-ASP product adoption to restore growth.
Product Mix & Market SoftnessA shift to lower-ASP products and softer elective procedure demand structurally depress average selling prices and top-line growth. Even with high gross margins, adverse mix reduces per-procedure economics and makes margin expansion dependent on execution of higher-ASP launches and a cyclical recovery in elective volumes.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $1.19 and its highest was $8.87 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $82.68M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is May 13, 2026 which is in 46 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on Feb 27, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.002.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.31.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 64,590,500 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went down -11.429%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.56 (178.13% Upside)
$3.56 (178.13% Upside)
Blogger Sentiment
Bullish
TMCI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 120.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.80%
12-Months-Change
Fundamentals
Return on Equity
-51.63%
Trailing 12-Months
Asset Growth
-7.67%
Trailing 12-Months
Company Description
Treace Medical Concepts
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
TMCI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: the company demonstrated meaningful operational progress — expanding its product portfolio, accelerating surgeon adoption, materially reducing cash burn and improving full-year adjusted EBITDA vs prior year — and secured liquidity. However, these positives are offset by near-term revenue pressure driven by a mix shift toward lower-priced products, market softness in elective foot and ankle procedures, a sizable Q4 GAAP net loss increase, and guidance that implies flat-to-declining revenue for 2026 with an expectation of an adjusted EBITDA loss. Management expects improvements later in 2026 (stronger Q3/Q4) as new higher-ASP products launch and adoption deepens, but the current outlook and recent quarterly results temper the outlook.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$3.56
▲(178.13% Upside)
Technical Analysis
Ownership Overview
29.16% Insiders
8.91% Mutual Funds
24.97% Other Institutional Investors
29.53% Public Companies and
Individual Investors